Extended Data Fig. 8: Schematic of the proposed LMP1-based CD4 CTL therapeutic strategy. | Nature

Extended Data Fig. 8: Schematic of the proposed LMP1-based CD4 CTL therapeutic strategy.

From: Mechanism of EBV inducing anti-tumour immunity and its therapeutic use

Extended Data Fig. 8: Schematic of the proposed LMP1-based CD4 CTL therapeutic strategy.The alternative text for this image may have been generated using AI.

Ectopically expressing LMP1 in tumour B cells from patients with cancer will (1) enhance presentation of endogenous antigens, such as TAAs and neoantigens, on MHC-II, and (2) provide costimulation through CD70 and OX40L, thereby eliciting CD4 CTLs against these tumour antigens. CD4 CTLs generated in this fashion will mediate cytotoxicity to unmodified tumour B cells that express the same antigens.

Back to article page